Pharmaceutical Technology

FEBRUARY 3, 2023

The established method for this process is a triple transfection using three different DNA plasmids. Better transfection reagents and efforts to automate the currently highly manual and inconsistent process could also make a difference, he adds. For example, researchers have developed a two-plasmid cotransfection system.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. Elsewhere around the globe: RevoluGen – U.K.-based for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

JULY 11, 2021

TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. All antibody titres were low. 2.4% (2/84) of lanadelumab-treated subjects tested positive for neutralizing antibodies.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52